Condition: Huntington Disease · Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Evaluate the safety and tolerability of combined oral thiamine with biotin therapy in patients with Huntington´s disease in mild to moderate stages and it is intended to evaluate the biological effect of the treatment in the central nervous system of these patients using as the main biomarker the increase in the level of thiamine monophosphate (TMP) in cerebrospinal fluid (CSF) of these patients with Huntington Disease (HD) during a follow-up period of one year. Our main hypothesis is that combined thiamine-biotin oral therapy is a secure and well-tolerated treatment, potentially capable of modifying the disease course or avoiding the progression of symptoms in early-stages HD patients
This description comes directly from the study's public registry record.
Pablo Mir Rivera, MD/PhD · +34 955923039 · pmir@us.es
Clara M. Rosso Fernández, MD/PhD · +34 955012144 · claram.rosso.sspa@juntadeandalucia.es
Always discuss trial participation with your own doctor first.
| Hospital Universitario de San Sebastián | San Sebastián, San Sebastian, Spain | Recruiting |
| Virgen del Rocío Hospital | Seville, Seville, Spain | Recruiting |
| Hospital Ramón y Cajal | Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04478734